Lipocine announces financial results for the first quarter ended march 31, 2023

Salt lake city , may 11, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the first quarter ended march 31, 2023, and provided a corporate update. first quarter highlights neuroactive steroid for depression dosing was initiated in a pilot clinical bridge study of lpcn 1154 (oral brexanolone) a neuroactive steroid product candidate that lipocine is developing for postpartum depression ("ppd").
LPCN Ratings Summary
LPCN Quant Ranking